UK-based private equity firm Exponent has held the final close of its fifth flagship fund, Exponent Private Equity Partners V, raising €1.2bn – surpassing its original target by 20%, according to a report by Bloomberg.
The oversubscribed fund attracted commitments from a globally diversified investor base that includes pension funds, sovereign wealth funds, endowments, and family offices, according to a statement.
Fund V will continue Exponent’s established strategy of backing mid-market businesses across Europe, with a focus on founder-, family- and corporate-owned companies with enterprise values between €150m and €500m. The firm typically looks to be the first institutional investor in its portfolio companies.
The fund has already deployed capital into four investments, including Chanelle Pharma, a European generic and veterinary pharmaceutical company; data centre design specialist Ethos Engineering; Kingsbridge Healthcare Group, Northern Ireland’s largest private healthcare provider; and digital consultancy Hippo Digital.
Founded in 2004, Exponent has built a track record of partnering with management teams to accelerate growth in companies across sectors including healthcare, technology, industrials, and business services.
